Beyond Air (XAIR) Q1 2026 earnings review
Growth Stalls as the Company Awaits Gen-2 FDA Approval
Despite management's claim of entering a 'new phase of commercial execution,' Beyond Air's revenue growth has severely decelerated. Revenue for the quarter ended June 30, 2026, was $1.8 million—essentially flat year-over-year and down from a peak of $2.2 million two quarters ago. The company is effectively in a holding pattern, aggressively cutting R&D expenses to preserve cash while banking entirely on the FDA approval of its second-generation LungFit PH system in the second half of 2026. A recent $30.1 million financing package provides a lifeline, but with $10 million of those funds explicitly tied to the FDA approval, execution risk remains high.
🐂 Bull Case
The company signed its third major U.S. Group Purchasing Organization (GPO) agreement, adding nearly 2,000 U.S. hospitals to its network. International distribution also expanded to cover over 45 countries.
If approved in 2H CY2026, the second-generation LungFit PH system will offer transport capabilities, drastically expanding the addressable market and serving as the primary catalyst for the projected >110% revenue jump in CY2027.
🐻 Bear Case
Year-over-year revenue growth dropped from triple digits in early 2025 to 0% this quarter. The market may be experiencing the 'Osborne Effect,' where hospitals delay Gen-1 purchases in anticipation of the superior Gen-2 product.
While gross margin improved from 9% to 13% YoY, it remains fundamentally too low to support profitability at current volume levels, making the company highly dependent on future scale.
⚖️ Verdict: 🔴
Bearish. The narrative of commercial momentum is directly contradicted by flat revenue and a heavy reliance on a pending FDA approval. Until Gen-2 launches, the financials will likely remain strained.
Key Themes
Data Contradicts the Growth Narrative
Management stated they are 'entering an important new phase of commercial execution and a potential inflection point for revenue growth.' However, the hard data shows a reversing trend: revenue was completely flat YoY at $1.8 million and has sequentially declined from $1.9 million in the prior quarter and $2.2 million the quarter before that. The current Gen-1 commercial momentum has clearly stalled.
Second-Generation LungFit PH Innovation
The entire future financial trajectory hinges on the second-generation LungFit PH system. This cylinder-free, phasic flow nitric oxide generator reduces size and unlocks critical air/ground transport capabilities. The PMA supplement is currently under FDA review, with approval expected in the second half of CY2026.
Aggressive GPO Expansion
Beyond Air secured a contract with a third leading U.S. Group Purchasing Organization (GPO). Combined with prior agreements (Premier and Vizient), this removes significant contracting friction and immediately expands the company's reach by nearly 2,000 additional U.S. hospitals and health systems.
Financing Tied to Regulatory Milestones
The company bolstered its balance sheet with up to $30.1 million in financing post-quarter. However, only $10.2 million was upfront. Another $10.0 million from warrant exercises is strictly contingent upon FDA approval of the Gen-2 LungFit PH system. If the FDA delays or denies the supplement, the company loses access to a critical third of its capital.
Cost Cutting Preserves Runway
With revenue flat, management heavily pulled back on expenses to survive until the Gen-2 launch. R&D expenses were slashed by 35% year-over-year (from $3.1M to $2.0M). SG&A remained relatively stable at $4.9M. This disciplined cash management is necessary to maintain operations through the regulatory waiting period.
Anemic Gross Margins
Gross margin increased slightly to 13% for the quarter (up from 9% a year ago). However, generating just $225,000 in gross profit on $1.8 million in sales is deeply insufficient to cover ~$6.9 million in quarterly operating expenses. Meaningful profitability is mathematically impossible without both massive volume expansion and higher-margin hardware (Gen-2).
Other KPIs
Stable YoY. The net loss attributable to common stockholders expanded slightly from $7.7 million a year ago. While operating expenses were reduced, other expenses spiked to $1.5 million (up from $0.5M), likely driven by interest expenses from recent debt facilities.
Represents reported cash, restricted cash, and marketable securities as of June 30, 2026. Pro-forma cash is significantly higher due to the $10.2 million upfront gross proceeds from the post-quarter financing.
Guidance
Stable. The company reaffirmed its CY2026 guidance, which explicitly does not include any revenue from the second-generation LungFit PH system. This implies continued, slow grinding adoption of the Gen-1 system.
Accelerating. The midpoint of $17.0 million represents >110% year-over-year growth compared to CY2026. This aggressive forecast is entirely dependent on the successful approval and commercial launch of the Gen-2 LungFit PH system.
Key Questions
Gen-1 Cannibalization
With revenue stalling at $1.8 million, to what extent are hospitals delaying their LungFit PH implementations in order to wait for the more capable Gen-2 system?
FDA Communication
Given that $10 million in warrant financing is tied directly to the FDA approval of the Gen-2 system, what specific feedback have you received from the FDA during the PMA supplement review process?
Margin Scaling
Gross margins are currently sitting at 13%. What is the specific bridge to get gross margins to the targeted 60-70% range once Gen-2 is launched?